Linagliptin/Metformin Clonmel

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Linagliptin/Metformin Clonmel (Metformin Hydrochloride, Linagliptin)

Q: What is Linagliptin/Metformin Clonmel used for?

Linagliptin/Metformin Clonmel is a fixed‑dose oral medication indicated for the treatment of type 2 diabetes mellitus in adults. It combines a DPP‑4 inhibitor with a biguanide to improve blood glucose control when diet, exercise, or single‑agent therapy are insufficient.

Q: How does linagliptin work in this combination?

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher levels of endogenous GLP‑1. This enhances glucose‑dependent insulin secretion and reduces glucagon release, contributing to lower blood glucose concentrations.

Q: What is the usual dose of Linagliptin/Metformin?

The specific dose of Linagliptin/Metformin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Linagliptin/Metformin safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Q: How do I order Linagliptin/Metformin from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Linagliptin/Metformin compare with other antidiabetic options?

Compared with metformin alone, the addition of linagliptin provides a complementary mechanism that enhances insulin secretion without increasing hypoglycaemia risk. Unlike sulfonylureas, it does not cause insulin release independent of glucose levels, offering a lower hypoglycaemia profile.

Q: What are the storage requirements for Linagliptin/Metformin?

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed until use.

Q: How is Linagliptin/Metformin administered?

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Linagliptin/Metformin?

Serious risks include lactic acidosis (especially in patients with renal or hepatic impairment), pancreatitis, severe allergic reactions, and significant hypoglycaemia when combined with insulin or sulfonylureas. Patients should be educated to recognize symptoms and seek immediate medical attention if they occur.

Q: Who should not use Linagliptin/Metformin?

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain hepatic conditions unless deemed appropriate by a physician.

Linagliptin, the active ingredient in Linagliptin/Metformin Clonmel, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient.

GNH India supplies Linagliptin/Metformin Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Manufacturer / TM Owner

Clonmel Healthcare Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways.

Type 2 diabetes mellitus: improves overall glycemic control when monotherapy is inadequate.
Adults with type 2 diabetes inadequately controlled on metformin alone: provides additional glucose‑lowering effect.
Patients requiring combination therapy: offers dual mechanisms to reduce fasting and post‑prandial glucose levels.

How It Works

Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), which raises endogenous GLP‑1 concentrations and enhances glucose‑dependent insulin secretion. Metformin hydrochloride suppresses hepatic gluconeogenesis and increases peripheral insulin sensitivity, together lowering blood glucose levels without causing hypoglycaemia when used alone.

Side Effects

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhoea: loose stools, often transient.
Abdominal discomfort: cramping or pain.
Headache: mild tension‑type headaches.
Dizziness: occasional light‑headedness.
Hypoglycaemia (when combined with sulfonylureas or insulin): low blood sugar episodes.

Serious or Rare Side Effects

Lactic acidosis: rare but life‑threatening metabolic disturbance.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic dysfunction: abnormal liver enzymes or jaundice.
Renal impairment: worsening kidney function.
Severe hypoglycaemia: prolonged low blood glucose requiring assistance.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific factors.

Renal function assessment: check eGFR to ensure safe metformin use.
Hepatic disease monitoring: assess liver enzymes periodically.
Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment.
Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
Drug interaction review: consider concomitant medications that may affect glucose control.
Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin/Metformin may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicates metformin use.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
Iodinated contrast agents: can precipitate metformin‑associated lactic acidosis.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: heightened risk of hypoglycaemia, dose adjustments may be needed.
Alcohol consumption: may increase the risk of metformin‑related lactic acidosis.

Frequently Asked Questions

Linagliptin/Metformin Clonmel is a fixed‑dose oral medication indicated for the treatment of type 2 diabetes mellitus in adults. It combines a DPP‑4 inhibitor with a biguanide to improve blood glucose control when diet, exercise, or single‑agent therapy are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher levels of endogenous GLP‑1. This enhances glucose‑dependent insulin secretion and reduces glucagon release, contributing to lower blood glucose concentrations.

The specific dose of Linagliptin/Metformin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with metformin alone, the addition of linagliptin provides a complementary mechanism that enhances insulin secretion without increasing hypoglycaemia risk. Unlike sulfonylureas, it does not cause insulin release independent of glucose levels, offering a lower hypoglycaemia profile.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed until use.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed by a healthcare professional.

Serious risks include lactic acidosis (especially in patients with renal or hepatic impairment), pancreatitis, severe allergic reactions, and significant hypoglycaemia when combined with insulin or sulfonylureas. Patients should be educated to recognize symptoms and seek immediate medical attention if they occur.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with certain hepatic conditions unless deemed appropriate by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.